Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04495790 · ClinicalTrials.gov registry record

AIMS Cancer Outcomes Study

A clinical trial of Advanced Solid Tumor and Neoplasms, sponsored by Advanced Integrative Medical Science Institute.

Recruiting
Registry status
500
Enrollment target
1
Study location

NCT04495790: Recruiting study of Advanced Solid Tumor and Neoplasms, sponsored by Advanced Integrative Medical Science Institute.

NCT04495790 is a study of Advanced Solid Tumor and Neoplasms that is actively recruiting participants, run by Advanced Integrative Medical Science Institute. The registered enrollment target is 500 participants, above the 190-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (163% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04495790, a study of Advanced Solid Tumor and Neoplasms, is actively recruiting participants, sponsored by Advanced Integrative Medical Science Institute.

RECRUITING
Registry status
500 participants
Enrollment target
1
Study location

Study Summary

The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment in a prospective consecutive case series outcomes study. We will collect data and study outcomes for patients with cancer who receive care at AIMS Institute.

Primary Outcome

Measure DFS and OS in advanced stage cancer patients who receive AIO treatments at AIMS Institute.

Conditions Studied

Advanced Solid Tumor Neoplasms Advanced Cancer Oncology Neoplasm Malignant

Study Locations (1)

Washington

  • AIMS Institute - Seattle

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2020-05-18
Est. Completion 2030-12-31
Advanced Integrative Medical Science Institute

2 total trials

What NCT04495790 shows while recruiting

NCT04495790 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 190-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (163% higher).

The record links to 5 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 0 interventions.

NCT04495790 reports a single indexed study location in Washington.

Frequently Asked Questions

What is clinical trial NCT04495790 about?

NCT04495790 is a clinical study titled "AIMS Cancer Outcomes Study". The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment in a prospective consecutive case series outcomes study. We will collect d...

What is the current status of trial NCT04495790?

This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2020-05-18. Estimated completion is 2030-12-31.

What conditions does trial NCT04495790 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Neoplasms, Advanced Cancer, Oncology, Neoplasm Malignant.

Who is sponsoring clinical trial NCT04495790?

This trial is sponsored by Advanced Integrative Medical Science Institute, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04495790 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04495790's enrollment target sits among peer trials

500 9th of 189 higher than 181 of 189 other Advanced Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT04495790

Source: ClinicalTrials.gov NCT04495790, the US trial registry maintained by the National Library of Medicine. NCT04495790 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.